Working… Menu

Docetaxel With or Without AZD6244 in Melanoma (DOC-MEK)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01256359
Recruitment Status : Active, not recruiting
First Posted : December 8, 2010
Last Update Posted : May 4, 2018
Information provided by (Responsible Party):
University of Oxford

Brief Summary:
This is a randomised, double-blind placebo controlled phase 2 trial. Patient will be randomly assigned 1:1 between 2 treatment arms. They will receive either docetaxel 75mg/m2 IV and placebo given bd, or AZD6244 75mg bd daily with docetaxel 75mg/m2 IV. Docetaxel will be administered every 3 weeks for a maximum 6 cycles, but AZD6244/placebo may be continued beyond this, until disease progression. The objective is to assess whether the combination of AZD6244 with docetaxel is worthy of evaluation in a definitive randomised study, with the null hypothesis being that the combination has activity similar to that of docetaxel alone in this population. After consent has been obtained mutational analysis of tumour BRAF will be performed on archival tumour tissue, where this information is not already known, to assess eligibility for the study. If there is no archival tissue a fresh biopsy will be requested from the patient. A blood sample will also be taken for future genetic analysis. Once taking part in the trial patients will need to attend their oncology unit regularly for monitoring and the delivery of treatment. Patients will undergo complete physical examination at screening, on C1D1, C1D8, C1D15, C2D1, C2D8 and day 1 of every subsequent cycle. Blood for haematology, biochemistry and clotting will be taken at each of these visits. A 12 lead ECG will be performed at screening . Disease assessment will be by CT scanning using modified RECIST criteria after 9 and 18 weeks, then every 3 months until disease progression.

Condition or disease Intervention/treatment Phase
Melanoma Drug: Docetaxel and AZD6244 Drug: Docetaxel and placebo Phase 2

Detailed Description:
No further information in addition to what has been provided in the brief summary

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double Blind Randomised Phase 2 Trial of Docetaxel With or Without AZD6244 in wt BRAF Advanced Melanoma
Study Start Date : October 2010
Actual Primary Completion Date : October 2012
Estimated Study Completion Date : December 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Melanoma
Drug Information available for: Docetaxel

Arm Intervention/treatment
Experimental: Docetaxel and AZD6244
Docetaxel with AZD6244
Drug: Docetaxel and AZD6244
Docetaxel 75mg/m2 IV and AZD6244 75mg bd daily. Docetaxel will be administered every 3 weeks for a maximum 6 cycles, but AZD6244 may be continued beyond this, until disease progression.
Other Name: Taxotere

Experimental: Docetaxel and Placebo
Docetaxel without AZD6244
Drug: Docetaxel and placebo
Docetaxel 75mg/m2 IV and placebo given bd. Docetaxel will be administered every 3 weeks for a maximum 6 cycles, but placebo may be continued beyond this, until disease progression.
Other Name: Taxotere

Primary Outcome Measures :
  1. Progression Free Survival [ Time Frame: Analysis will be performed when approximately 58 disease progression/death events have occurred. Average time 7 months. ]
    To assess the efficacy of AZD6244 in combination with docetaxel, compared with docetaxel alone, in first line patients with wild type BRAF advanced malignant melanoma

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   16 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Aged >/= 16 years
  • Able to provide evidence from an accredited laboratory of wt BRAF status for their melanoma, or ascertainment of wt BRAF status from a sample of melanoma provided for mutational analysis in Oxford.
  • Unresectable stage 3 or 4, histologically proven cutaneous or unknown primary melanoma
  • At least 1 lesion, not previously irradiated, that can be accurately measured on CT or MRI as defined by modified RECIST criteria
  • ECOG performance score of 0 or 1.
  • Life expectancy of at least 12 weeks.
  • The patient is willing to give consent to the main study and able to comply with the protocol for the duration of the study, including scheduled follow-up visits and examinations.
  • Haematological and biochemical indices within the ranges shown below. Lab Test Value required Haemoglobin (Hb) >10g/dL White Blood Count (WBC) > 3x109/L Platelet count > 100,000/μL Absolute Neutrophil count > 1.5x109/L; Serum bilirubin ≤ 1.2 x ULN AST (SGOT) or ALT ≤ 2.5 x ULN LDH ≤ 2 x ULN Creatinine clearance (Cockcroft-Gault) >50 ml/min

Exclusion Criteria:

  • Any anti-cancer therapy (including radiotherapy and participation in other clinical trials) within 28 days prior to Day 1.
  • Prior DNA damaging agents or cytotoxic chemotherapy for metastatic melanoma.
  • Any unresolved toxicity from prior anti-cancer therapy that is greater than CTCAE grade 2.
  • Pregnancy or breastfeeding women. Female patients must have a negative urinary or serum pregnancy test or have evidence of post-menopausal status (defined as absence of menstruation for > 12 months, bilateral oophrectomy or hysterectomy).
  • Grade ≥2 peripheral neuropathy at study entry.
  • Patients of reproductive potential who are not willing to use adequate contraceptive measures for the duration of the study (both male and female patients)
  • Known severe hypersensitivity reactions to docetaxel or other drugs formulated in polysorbate 80
  • Ocular or mucosal malignant melanoma
  • Another active malignancy within the past five years.
  • Evidence of brain metastases, unless surgically resected/stereotactic radiosurgery treated brain metastasis with no evidence of relapse on cerebral MRI, or treated brain metastasis and stable off treatment, including steroids, for 3 months.
  • Clinically significant and uncontrolled major medical condition(s): such as active infection, bleeding diathesis.
  • Patients who are known to be serologically positive for Hepatitis B, Hepatitis C or HIV.
  • Cardiac conditions, including uncontrolled hypertension (BP>160/100 despite treatment), heart failure NYHA class 2 or above, prior or current cardiomyopathy, myocardial infarction within 6 months or angina requiring nitrate therapy more than once a week.
  • Previous treatment with EGFR, ras, raf or MEK inhibitors.
  • Inability to swallow capsules, refractory nausea and vomiting, chronic gastrointestinal diseases (eg, inflammatory bowel disease) or significant bowel resection that would preclude adequate absorption.
  • Taking medication that significantly induces or inhibits CYP3A4.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01256359

Layout table for location information
United Kingdom
Churchill Hospital
Oxford, Oxfordshire, United Kingdom, OX3 7LJ
Sponsors and Collaborators
University of Oxford
Layout table for investigator information
Principal Investigator: Mark R Middleton University of Oxford

Layout table for additonal information
Responsible Party: University of Oxford Identifier: NCT01256359     History of Changes
Other Study ID Numbers: OCTO_015
First Posted: December 8, 2010    Key Record Dates
Last Update Posted: May 4, 2018
Last Verified: May 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action